secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001104659-23-038778
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics reports $41.8M cash, Q4 2022 results; VCN-01 trials advance
-----------------------------------------------------------------------------

- Cash and equivalents $41.8M as of Dec 31, 2022, down from $67.3M; runway into Q3 2024.
- G&A expenses $9.9M (+50.8% YoY); R&D expenses $11.7M (+50% YoY) driven by VCN-01 trials.
- First patient dosed in VIRAGE Phase 2b trial of VCN-01 for metastatic pancreatic cancer (Jan 2023).
- First patient dosed in investigator-sponsored Phase 1 trial of VCN-01 for brain tumors (Jan 2023).
- SYN-004 Phase 1b/2a in allo-HCT: blinded safety/PK data presented at Tandem Meetings (Feb 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465923038778/0001104659-23-038778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465923038778/tm2310776d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-038778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer